Surgery for Obesity and Related Diseases最新文献

英文中文

SOARD Category 1 CME Credit Featured Articles, Volume 21, January 2025

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-01-01 DOI: 10.1016/j.soard.2024.11.009

引用次数: 0

Paired editorial for “GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study” GLP-1受体激动剂与腹腔镜袖带胃切除术后恶心呕吐的风险：一项单中心回顾性队列研究 "的配对社论。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-20 DOI: 10.1016/j.soard.2024.12.007

Boris Zevin M.D., Ph.D., F.A.C.S.

引用次数: 0

Comment on: Perioperative lifestyle and nutritional interventions' details reporting in bariatric surgery trials according to the TIDieR checklist: a cross-sectional study 评论：根据TIDieR检查表，减肥手术试验中围手术期生活方式和营养干预的细节报告：一项横断面研究。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-18 DOI: 10.1016/j.soard.2024.12.010

Michael Kachmar D.O., Florina Corpodean M.D., Vance L. Albaugh M.D., Ph.D.

引用次数: 0

Comment on: 10-year outcomes of marginal ulcer formation and impact of gastrojejunostomy technique in Roux-en-Y gastric bypass 评论：Roux-en-Y胃旁路术中边缘溃疡形成的10年预后和胃空肠造口技术的影响。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-18 DOI: 10.1016/j.soard.2024.12.009

Ramsey Michael Dallal M.D.

引用次数: 0

Pregnancy and birth complications among women undergoing bariatric surgery: sleeve gastrectomy versus Roux-en-Y gastric bypass 接受减肥手术妇女的妊娠和分娩并发症：袖式胃切除术与Roux-en-Y胃旁路术

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-16 DOI: 10.1016/j.soard.2024.11.012

Shavonne E. Osiakwan B.S., Kiana S. Jones B.S., Swathi B. Reddy M.D., Philip Omotosho M.D., Nicholas J. Skertich M.D., M.S., Alfonso Torquati M.D.

Background

Metabolic bariatric surgery is the most effective therapy for severe obesity, which affects the health of millions, most of whom are women of child-bearing age. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the most common bariatric procedures and are associated with durable weight loss and comorbidity resolution. Although obstetric outcomes broadly improve, the safety profile comparing the impact of RYGB and SG on obstetric outcomes is underexplored.

Objectives

To compare obstetric outcomes in women who gave birth post-RYGB versus SG to determine whether there are differences in perinatal outcomes.

Setting

United States, all patients within commercial, Medicare, Medicaid, government, and cash payor systems.

Methods

The PearlDiver-Mariner database was used to identify women aged 18–52 years who underwent RYGB or SG between 2010 and 2020 and became pregnant within 2 years of surgery. Outcomes were defined by the presence of 1 or more pregnancy-related complications including gestational diabetes, preeclampsia, and hysterectomy. A 1:1 propensity-matched analysis was performed.

Results

In total, 16,911 individuals, 10,675 (63.1%) and 6236 (36.9%) underwent SG and RYGB, respectively. Obstetric complication rates were 28.3% in the SG versus 32.1% in the RYGB group (P < .01). The RYGB group had an increased relative odds of experiencing an obstetric complication compared with the SG group (odds ratio 1.26; 95% confidence interval 1.14–1.38).

Conclusions

Although both are safe, RYGB was associated with a greater obstetric complication rate than SG. These findings can help women and surgeons decide which procedure to pursue and inform discussions regarding the timing of pregnancy after surgery.

背景：代谢减肥手术是治疗严重肥胖最有效的方法，严重肥胖影响数百万人的健康，其中大多数是育龄妇女。Roux-en-Y胃旁路手术（RYGB）和袖胃切除术（SG）是最常见的减肥手术，与持久的体重减轻和合并症的解决有关。虽然产科结果普遍改善，但比较RYGB和SG对产科结果的影响的安全性尚未得到充分探讨。目的：比较rygb和SG后分娩的妇女的产科结局，以确定围产期结局是否存在差异。环境：美国，商业、医疗保险、医疗补助、政府和现金支付系统内的所有患者。方法：PearlDiver-Mariner数据库用于识别在2010年至2020年期间接受RYGB或SG手术并在2年内怀孕的18-52岁女性。结果定义为出现1种或1种以上妊娠相关并发症，包括妊娠糖尿病、先兆子痫和子宫切除术。进行1:1倾向匹配分析。结果：共16911例，10675例（63.1%）和6236例（36.9%）分别接受了SG和RYGB治疗。SG组的产科并发症发生率为28.3%，而RYGB组为32.1% （P < 0.01）。与SG组相比，RYGB组发生产科并发症的相对几率增加(优势比1.26；95%置信区间1.14-1.38)。结论：虽然两者都是安全的，但RYGB的产科并发症发生率高于SG。这些发现可以帮助妇女和外科医生决定采用哪种手术，并为手术后怀孕时间的讨论提供信息。

{"title":"Pregnancy and birth complications among women undergoing bariatric surgery: sleeve gastrectomy versus Roux-en-Y gastric bypass","authors":"Shavonne E. Osiakwan B.S., Kiana S. Jones B.S., Swathi B. Reddy M.D., Philip Omotosho M.D., Nicholas J. Skertich M.D., M.S., Alfonso Torquati M.D.","doi":"10.1016/j.soard.2024.11.012","DOIUrl":"10.1016/j.soard.2024.11.012","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic bariatric surgery is the most effective therapy for severe obesity, which affects the health of millions, most of whom are women of child-bearing age. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the most common bariatric procedures and are associated with durable weight loss and comorbidity resolution. Although obstetric outcomes broadly improve, the safety profile comparing the impact of RYGB and SG on obstetric outcomes is underexplored.</div></div><div><h3>Objectives</h3><div>To compare obstetric outcomes in women who gave birth post-RYGB versus SG to determine whether there are differences in perinatal outcomes.</div></div><div><h3>Setting</h3><div>United States, all patients within commercial, Medicare, Medicaid, government, and cash payor systems.</div></div><div><h3>Methods</h3><div>The PearlDiver-Mariner database was used to identify women aged 18–52 years who underwent RYGB or SG between 2010 and 2020 and became pregnant within 2 years of surgery. Outcomes were defined by the presence of 1 or more pregnancy-related complications including gestational diabetes, preeclampsia, and hysterectomy. A 1:1 propensity-matched analysis was performed.</div></div><div><h3>Results</h3><div>In total, 16,911 individuals, 10,675 (63.1%) and 6236 (36.9%) underwent SG and RYGB, respectively. Obstetric complication rates were 28.3% in the SG versus 32.1% in the RYGB group (<em>P</em> < .01). The RYGB group had an increased relative odds of experiencing an obstetric complication compared with the SG group (odds ratio 1.26; 95% confidence interval 1.14–1.38).</div></div><div><h3>Conclusions</h3><div>Although both are safe, RYGB was associated with a greater obstetric complication rate than SG. These findings can help women and surgeons decide which procedure to pursue and inform discussions regarding the timing of pregnancy after surgery.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 4","pages":"Pages 509-515"},"PeriodicalIF":3.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabis use before and after metabolic and bariatric surgery: literature review

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-15 DOI: 10.1016/j.soard.2024.12.006

Kasey P.S. Goodpaster Ph.D. , Rheanna Ata Brown Ph.D. , Amanda M. Van Prooyen Pharm.D., B.C.P.S. , Katie Chapmon M.S., R.D. , Melissa Santos Ph.D. , Gwen Crispell M.S.N., R.N., C.B.N. , David B. Sarwer Ph.D.

As accessibility and legalization of cannabis rise throughout the United States (US), programs have sought guidance about whether its use should be considered a contraindication or, if not a contraindication, what recommendations patients should receive regarding appropriate use before and after metabolic and bariatric surgery (MBS). In this review, medical, nutritional, pharmacological, and psychological considerations are presented by a multidisciplinary group of members of the American Society for Metabolic and Bariatric Surgery (ASMBS). Research suggests several risks associated with long-term cannabis use in the general population, but research in the MBS population, specifically, is limited. Cannabis use is not associated with most postoperative complications but is associated with mental health concerns and disordered eating in patients who have undergone MBS. Research regarding weight loss outcomes is mixed, with most studies showing no significant association. Severe cannabis use appears to have more clinical significance than mild to moderate use, as it is associated with longer lengths of stay and medical complications. While an active cannabis use disorder is considered a contraindication, requiring treatment and abstinence before proceeding with surgery, the state of the literature is not strong enough to suggest that occasional or medical cannabis use is an absolute contraindication to MBS. Decisions about cannabis protocols should be made at the MBS program level, and patients should be fully informed about the risks of ongoing use.

{"title":"Cannabis use before and after metabolic and bariatric surgery: literature review","authors":"Kasey P.S. Goodpaster Ph.D. , Rheanna Ata Brown Ph.D. , Amanda M. Van Prooyen Pharm.D., B.C.P.S. , Katie Chapmon M.S., R.D. , Melissa Santos Ph.D. , Gwen Crispell M.S.N., R.N., C.B.N. , David B. Sarwer Ph.D.","doi":"10.1016/j.soard.2024.12.006","DOIUrl":"10.1016/j.soard.2024.12.006","url":null,"abstract":"<div><div>As accessibility and legalization of cannabis rise throughout the United States (US), programs have sought guidance about whether its use should be considered a contraindication or, if not a contraindication, what recommendations patients should receive regarding appropriate use before and after metabolic and bariatric surgery (MBS). In this review, medical, nutritional, pharmacological, and psychological considerations are presented by a multidisciplinary group of members of the American Society for Metabolic and Bariatric Surgery (ASMBS). Research suggests several risks associated with long-term cannabis use in the general population, but research in the MBS population, specifically, is limited. Cannabis use is not associated with most postoperative complications but is associated with mental health concerns and disordered eating in patients who have undergone MBS. Research regarding weight loss outcomes is mixed, with most studies showing no significant association. Severe cannabis use appears to have more clinical significance than mild to moderate use, as it is associated with longer lengths of stay and medical complications. While an active cannabis use disorder is considered a contraindication, requiring treatment and abstinence before proceeding with surgery, the state of the literature is not strong enough to suggest that occasional or medical cannabis use is an absolute contraindication to MBS. Decisions about cannabis protocols should be made at the MBS program level, and patients should be fully informed about the risks of ongoing use.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 4","pages":"Pages 345-353"},"PeriodicalIF":3.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to “Racial disparities in the utilization and outcomes of robotic bariatric surgery: correspondence” 对“机器人减肥手术的使用和结果的种族差异：通信”的回应。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-12 DOI: 10.1016/j.soard.2024.11.023

Qais AbuHasan M.D., Payton M. Miller M.D., Wendy S. Li M.D., Charles P. Burney M.D., M.P.H., Tarik K. Yuce M.D., M.S., Dimitrios Stefanidis M.D., Ph.D.

引用次数: 0

Comment on: “Assessment of predictors of acute kidney injury and progression to chronic kidney disease following bariatric surgery” 评论：“评估减肥手术后急性肾损伤和慢性肾病进展的预测因素”。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-12 DOI: 10.1016/j.soard.2024.12.005

Sean M. O’Neill M.D., Ph.D., Nabeel R. Obeid M.D.

引用次数: 0

Comparison of food tolerance among bariatric surgery procedures: a systematic review 减肥手术过程中食物耐受性的比较：一项系统综述。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-09 DOI: 10.1016/j.soard.2024.11.018

Silvia Leite Ph.D., Mary O’Kane R.D.

引用次数: 0

Bariatric surgery targeting opioid prescribing: a national model for effectively reducing opioid use after bariatric surgery 针对阿片类药物处方的减肥手术：一个有效减少减肥手术后阿片类药物使用的国家模式。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2024-12-09 DOI: 10.1016/j.soard.2024.11.011

Anthony T. Petrick M.D. , Tejen A. Shah M.D., M.B.A. , Dominick Gadaleta M.D. , Jon Gould M.D., M.B.A. , John Morton M.D., M.P.H. , April Smith Pharm.D. , Kimberly Evans-Labok B.A. , Leandra Knapp M.S. , Clifford Y. Ko M.D., M.S., M.S.H.S. , Stacy A. Brethauer M.D., M.B.A.

Background

Prescription opioids are responsible for a significant proportion of opioid-related deaths in the United States. Approximately 6% of opioid-naïve patients who receive opioid prescriptions after surgery become chronic opioid users. However, chronic opioid use after bariatric surgery may be twice as common.

Objectives

This study aimed to report the feasibility and efficacy of implementing a national opioid-reducing protocol and to determine the impact of this protocol on opioid use after bariatric surgery.

Setting

Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-accredited hospitals.

Methods

Bariatric surgery targeting opioid prescription (BSTOP) was a national project sponsored by the MBSAQIP. It was executed in 3 phases: baseline, pilot, and implementation. A total of 271 MBSAQIP-accredited centers implemented the BSTOP protocol and reported data for all 3 phases. Protocol adherence, inpatient opioid use, opioids discharge prescribing, and outpatient opioid use were analyzed. Hospital-level opioid prescription habits were also assessed.

Results

Compliance with 6 of 9 process measures improved significantly (P < .001). Median morphine milligram equivalents (MMEs) prescribed during inpatient stay decreased from 35 MMEs during data collection to 23 MMEs during the implementation phase (Dwass-Steel-Critchlow-Fligner, P < .001). Opioids prescribed at discharge decreased by 9.5% (P < .001). Low inpatient MME prescriptions were achieved by 14.2% of hospitals, while 15.7% of hospitals became low-discharge opioid prescribers.

Conclusions

Implementation of a national opioid-reducing protocol in bariatric surgery is feasible and effective in reducing opioid prescribing and use. However, the adoption of postdischarge prescription guidelines remains low. Opportunities to reduce the impact of prescription opioids on overdose deaths persist.

背景：处方阿片类药物在美国阿片类药物相关死亡中占很大比例。大约6%的opioid-naïve术后接受阿片类药物处方的患者成为慢性阿片类药物使用者。然而，减肥手术后慢性阿片类药物的使用可能是其两倍。目的：本研究旨在报告实施国家阿片类药物减少方案的可行性和有效性，并确定该方案对减肥手术后阿片类药物使用的影响。环境：代谢和减肥手术认证和质量改进计划（MBSAQIP）认可的医院。方法：靶向阿片类药物处方的减肥手术（BSTOP）是由MBSAQIP资助的国家项目。它分三个阶段执行：基线、试点和实施。共有271个mbsaqip认证中心实施了BSTOP协议，并报告了所有3个阶段的数据。分析方案依从性、住院阿片类药物使用、阿片类药物出院处方和门诊阿片类药物使用情况。还评估了医院一级的阿片类药物处方习惯。结果：9项工艺措施中6项的依从性明显改善（P < 0.001）。住院期间处方吗啡毫克当量（MMEs）的中位数从数据收集期间的35毫克当量下降到实施阶段的23毫克当量（dwassi - steel - critchlow - fligner, P < .001）。出院时阿片类药物处方减少9.5% （P < 0.001）。14.2%的医院实现了低住院MME处方，15.7%的医院成为低出院阿片类药物处方者。结论：在减肥手术中实施国家阿片类药物减少方案在减少阿片类药物处方和使用方面是可行和有效的。然而，出院后处方指南的采用率仍然很低。减少处方类阿片对过量死亡的影响的机会仍然存在。

{"title":"Bariatric surgery targeting opioid prescribing: a national model for effectively reducing opioid use after bariatric surgery","authors":"Anthony T. Petrick M.D. , Tejen A. Shah M.D., M.B.A. , Dominick Gadaleta M.D. , Jon Gould M.D., M.B.A. , John Morton M.D., M.P.H. , April Smith Pharm.D. , Kimberly Evans-Labok B.A. , Leandra Knapp M.S. , Clifford Y. Ko M.D., M.S., M.S.H.S. , Stacy A. Brethauer M.D., M.B.A.","doi":"10.1016/j.soard.2024.11.011","DOIUrl":"10.1016/j.soard.2024.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Prescription opioids are responsible for a significant proportion of opioid-related deaths in the United States. Approximately 6% of opioid-naïve patients who receive opioid prescriptions after surgery become chronic opioid users. However, chronic opioid use after bariatric surgery may be twice as common.</div></div><div><h3>Objectives</h3><div>This study aimed to report the feasibility and efficacy of implementing a national opioid-reducing protocol and to determine the impact of this protocol on opioid use after bariatric surgery.</div></div><div><h3>Setting</h3><div>Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-accredited hospitals.</div></div><div><h3>Methods</h3><div>Bariatric surgery targeting opioid prescription (BSTOP) was a national project sponsored by the MBSAQIP. It was executed in 3 phases: baseline, pilot, and implementation. A total of 271 MBSAQIP-accredited centers implemented the BSTOP protocol and reported data for all 3 phases. Protocol adherence, inpatient opioid use, opioids discharge prescribing, and outpatient opioid use were analyzed. Hospital-level opioid prescription habits were also assessed.</div></div><div><h3>Results</h3><div>Compliance with 6 of 9 process measures improved significantly (<em>P</em> < .001). Median morphine milligram equivalents (MMEs) prescribed during inpatient stay decreased from 35 MMEs during data collection to 23 MMEs during the implementation phase (Dwass-Steel-Critchlow-Fligner, <em>P</em> < .001). Opioids prescribed at discharge decreased by 9.5% (<em>P</em> < .001). Low inpatient MME prescriptions were achieved by 14.2% of hospitals, while 15.7% of hospitals became low-discharge opioid prescribers.</div></div><div><h3>Conclusions</h3><div>Implementation of a national opioid-reducing protocol in bariatric surgery is feasible and effective in reducing opioid prescribing and use. However, the adoption of postdischarge prescription guidelines remains low. Opportunities to reduce the impact of prescription opioids on overdose deaths persist.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 4","pages":"Pages 402-410"},"PeriodicalIF":3.5,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Surgery for Obesity and Related Diseases

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀